New immune cell therapy aims to stop blood cancer relapse after transplant
NCT ID NCT07285668
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-treat leukemias or related cancers. The main goal is to find a safe dose and watch for side effects like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donor immune cells with certain T and B cells removed (TCRαβ+/CD19+ depleted donor lymphocyte infusion)
What this could lead to
If safe and effective, this approach could help prevent blood cancer relapse after a stem cell transplant, improving long-term outcomes for high-risk patients.
What could go wrong
This is a very early, small safety study (Phase I) that is currently suspended. It may not show benefit, and there are risks like graft-versus-host disease or other serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Carbone Cancer Center
Madison, Wisconsin, 53792, United States